First-Line PARP Inhibitors—Emerging Side Effects Require Caution: A Case of PARPi-Induced Pneumonitis by Alistair McLaren, Douglas Cartwright, Ewen Ross, Patricia Roxburgh

Subjects: “…parpi…”
Get full text

PARP inhibitor resistance: the underlying mechanisms and clinical implications by He Li, Zhao-Yi Liu, Nayiyuan Wu, Yong-Chang Chen, Quan Cheng, Jing Wang

Subjects: “…PARPi…”
Get full text

Poly (ADP-Ribose) Polymerase inhibitors (PARPi) therapy response in an acral melanoma patient with EMSY gene amplification by George Nassief, BA, Omar H. Butt, MD, PhD, Alice Y. Zhou, MD, PhD, George Ansstas, MD

Subjects: Get full text

Development of 1-(4-(Substituted)piperazin-1-yl)-2-((2-((4-methoxybenzyl)thio)pyrimidin-4-yl)oxy)ethanones That Target Poly (ADP-Ribose) Polymerase in Human Breast Cancer Cells by Suresha N. Deveshegowda, Prashant K. Metri, Rashmi Shivakumar, Ji-Rui Yang, Shobith Rangappa, Ananda Swamynayaka, Muthu K. Shanmugam, Omantheswara Nagaraja, Mahendra Madegowda, Priya Babu Shubha, Arunachalam Chinnathambi, Sulaiman Ali Alharbi, Vijay Pandey, Kwang Seok Ahn, Peter E. Lobie, Basappa Basappa

Subjects: “…PARPi…”
Get full text

Neoadjuvant treatment in ovarian cancer: New perspectives, new challenges by Adamantia Nikolaidi, Elena Fountzilas, Elena Fountzilas, Florentia Fostira, Amanda Psyrri, Helen Gogas, Christos Papadimitriou

Subjects: Get full text

Implementing MyChoice® CDx HRD testing for the Nordics: lessons from 2021 to 2023 by Lea Milling Korsholm, Verena Broecker, Mansoor Raza Mirza, Maria Rossing

Subjects: Get full text

New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer by Ye Han, Xiaopeng Yu, Shuqiang Li, Ye Tian, Caigang Liu

Subjects: “…PARPi…”
Get full text

CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer by Jiachen Xuan, Richard B. Pearson, Elaine Sanij

Subjects: Get full text

Discovery of Novel 4-Hydroxyquinazoline Derivatives: In Silico, In Vivo and In Vitro Studies Using Primary PARPi-Resistant Cell Lines by Lijie Zhu, Binzhuo Liu, Feng Jin, Weilong Cao, Guangzhao Xu, Xinwei Zhang, Peng Peng, Dingding Gao, Bin Wang, Kairui Feng

Subjects: “…PARPi…”
Get full text

Effects of Neoadjuvant Chemotherapy in Ovarian Cancer Patients With Different Germline BRCA1/2 Mutational Status: A Retrospective Cohort Study by Mengdi Fu, Chengjuan Jin, Shuai Feng, Zongyang Jia, Lekai Nie, Yang Zhang, Jin Peng, Xia Wang, Hualei Bu, Beihua Kong

Subjects: Get full text

Clinical and radiological pattern of olaparib-induced interstitial lung disease by Alexandre Brudon, Dorine Fournier, Frédéric Selle, Emmanuel Seront, Rosa Conforti, Gwenaëlle Veyrac, Aurore Gouraud, Bénédicte Lebrun-Vignes, Antoine Khalil, Gérard Zalcman, Valérie Gounant

Subjects: Get full text

Advances in Combined Immunotherapy for Triple Negative Breast Cancer by WANG Hua, HU Xiaolei, LI Xingyu, DAI Ying

Subjects: Get full text

Homologous Recombination Deficiency Associated With Response to Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer Patients: The First Real-World Evidence From China by Jing Ni, Wenwen Guo, Qian Zhao, Xianzhong Cheng, Xia Xu, Rui Zhou, Hongyuan Gu, Chen Chen, Xiaoxiang Chen

Subjects: Get full text

Synchronous BRCA2 positive ovarian carcinoma with ALK positive NSCLC: Double trouble by Ullas Batra, Shrinidhi Nathany, Mansi Sharma, Anila Sharma, Sunil Pasricha, Vidya Menon, Joslia T. Jose, Anurag Mehta

Subjects: Get full text

PARP inhibitors as therapy for small cell lung carcinoma: A systematic review and meta-analysis of clinical trials by Samuel Pratama, Lowilius Wiyono, Martien Silviandy Setiawan, Brigitta Cindy Lauren

Subjects: “…PARPi…”
Get full text

Mechanisms of drug resistance in ovarian cancer by Klaudia Żak, Michał Piwoński, Paweł Stanicki, Karolina Kalicka, Justyna Nowaczek

Subjects: Get full text

A case of niraparib PARP-Inhibitor induced Sweet Syndrome in gynecologic cancer by Nora Badiner, Cody Carter, Yevgeniya Ioffe, Linda Hong

Subjects: Get full text

Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene by Azam Ghafoor, MD, Idrees Mian, MD, Cathy Wagner, BSN, Yvonne Mallory, BSN, Maria Garcia Agra, BSN, Betsy Morrow, BS, Jun S. Wei, PhD, Javed Khan, MD, Anish Thomas, M.B.B.S., MD, Manjistha Sengupta, PhD, Seth M. Steinberg, PhD, Raffit Hassan, MD

Subjects: Get full text

Niraparib for the treatment of metastatic ccRCC in a patient with CDK12 and RAD51C mutations: a case report by Xiaolong Yue, Chenkang Yang, Dandan Cao, Yue Li

Subjects: Get full text

Complete response to talazoparib in patient with pancreatic adenocarcinoma harboring somatic PALB2 mutation: A case report and literature review by Andrei Kachmazov, Larisa Bolotina, Anna Kornietskaya, Olesya Kuznetsova, Olesya Kuznetsova, Maxim Ivanov, Alexander Fedenko

Subjects: Get full text